Literature DB >> 20735873

[Acute hepatitis, but not A, B, or C: consider E].

Gunnar I Andriesse1, Mustafa Donmez, Jamie Vissers, Peter van Wijngaarden.   

Abstract

OBJECTIVE: To determine the percentage of hepatitis E virus (HEV) infections in serum samples from patients with negative serology for hepatitis A, B and C and to find out what may be the harmful consequences of a missed diagnosis of acute HEV infection.
DESIGN: Retrospective study.
METHOD: Serum samples were selected from patients with infectious hepatitis who tested negative for hepatitis A, B and C virus. Serum samples that had elevated alanine aminotransferase (ALT; > 34 U/l) were included in this study. All samples were then tested for HEV using an enzyme-linked immunosorbent assay (ELISA) and immunoblot assay. Of patients with serological evidence of acute HEV, files were checked for the originally documented diagnosis at hospital discharge.
RESULTS: In the period October 2007-September 2008, 139 serum samples met the inclusion criteria. In 23 serum samples the ELISA was positive (IgM positive and/or Ig total positive); in 16/23 serum samples immunoblot assay was also positive. The percentage of confirmed HEV infections was 11.5% (16/139). In only one patient was the originally documented diagnosis correct. Several patients underwent invasive diagnostic procedures and treatment as a result of an incorrect diagnosis.
CONCLUSION: Hepatitis E serology should be a standard tool in the diagnostic workup of infectious hepatitis patients in the Netherlands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735873

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  First case of anti-ganglioside GM1-positive Guillain-Barré syndrome due to hepatitis E virus infection.

Authors:  I Maurissen; A Jeurissen; T Strauven; D Sprengers; B De Schepper
Journal:  Infection       Date:  2011-08-30       Impact factor: 3.553

2.  Hepatitis E virus as a Cause of Acute Hepatitis in The Netherlands.

Authors:  Aletta T R Tholen; Janke Schinkel; Richard Molenkamp; C Wim Ang
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.